1. Home
  2. FRO vs APGE Comparison

FRO vs APGE Comparison

Compare FRO & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frontline Plc

FRO

Frontline Plc

HOLD

Current Price

$40.90

Market Cap

4.8B

ML Signal

HOLD

Logo Apogee Therapeutics Inc.

APGE

Apogee Therapeutics Inc.

HOLD

Current Price

$90.38

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRO
APGE
Founded
1985
2022
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.7B
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
FRO
APGE
Price
$40.90
$90.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
13
Target Price
$37.67
$109.67
AVG Volume (30 Days)
3.3M
1.0M
Earning Date
05-22-2026
05-12-2026
Dividend Yield
4.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$34.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.25
$34.34
52 Week High
$40.74
$95.32

Technical Indicators

Market Signals
Indicator
FRO
APGE
Relative Strength Index (RSI) 69.80 58.46
Support Level $33.68 $73.70
Resistance Level N/A $93.61
Average True Range (ATR) 1.61 5.02
MACD 0.55 0.62
Stochastic Oscillator 99.16 89.73

Price Performance

Historical Comparison
FRO
APGE

About FRO Frontline Plc

Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.

About APGE Apogee Therapeutics Inc.

Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Share on Social Networks: